Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of WCK 4873 in Healthy Adults
NCT02453529Phase 1Completed
- Sponsor
- Wockhardt
- Start
- Apr 2015
- Primary completion
- Jul 2015
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nafithromycin in community-acquired bacterial pneumonia (CAP), sponsored by Wockhardt. Primary endpoint: Epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of WCK 4873 at 48 hours. Started Apr 2015; status: completed.
02
Drugs
nafithromycin
03
Conditions
community-acquired bacterial pneumonia (CAP)
Beyond the preview
Go deeper on NCT02453529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02453529.